马拉维、南非和赞比亚成年男性和女性当天开始接受艾滋病毒治疗:SPRINT回顾性队列研究

Amy Huber, Kamban Hirasen, Alana T. Brennan, Bevis Phiri, Timothy Tcherini, Lloyd Mulenga, Prudence Haimbe, Hilda Shakwelele, Rose Nyirenda, Bilaal Wilson Matola, Andrews Gunda, Sydney Rosen
{"title":"马拉维、南非和赞比亚成年男性和女性当天开始接受艾滋病毒治疗:SPRINT回顾性队列研究","authors":"Amy Huber, Kamban Hirasen, Alana T. Brennan, Bevis Phiri, Timothy Tcherini, Lloyd Mulenga, Prudence Haimbe, Hilda Shakwelele, Rose Nyirenda, Bilaal Wilson Matola, Andrews Gunda, Sydney Rosen","doi":"10.12688/gatesopenres.14424.1","DOIUrl":null,"url":null,"abstract":"<ns4:p><ns4:bold>Background: </ns4:bold>Since 2017 global guidelines have recommended “same-day initiation” (SDI) of antiretroviral treatment (ART) for patients considered ready for treatment on the day of HIV diagnosis. Many countries have incorporated a SDI option into national guidelines, but SDI uptake is not well documented. We estimated average time to ART initiation at 12 public healthcare facilities in Malawi, five in South Africa, and 12 in Zambia.</ns4:p><ns4:p> <ns4:bold>Methods: </ns4:bold>We sequentially enrolled patients eligible to start ART between January 2018 and June 2019 and reviewed their medical records from the point of HIV diagnosis or first HIV-related interaction with the clinic to the earlier date of treatment initiation or 6 months. We estimated the proportion of patients initiating ART on the same day or within 7, 14, 30, or 180 days of baseline.</ns4:p><ns4:p> <ns4:bold>Results: </ns4:bold>We enrolled 826 patients in Malawi, 534 in South Africa, and 1,984 in Zambia. Overall, 88% of patients in Malawi, 57% in South Africa, and 91% in Zambia were offered and accepted SDI. In Malawi, most who did not receive SDI had not initiated ART ≤6 months. In South Africa, an additional 13% initiated ≤1 week, but 21% had no record of initiation ≤6 months. Among those who did initiate within 6 months in Zambia, most started ≤1 week. There were no major differences by sex. WHO Stage III/IV and tuberculosis symptoms were associated with delays in ART initiation.</ns4:p><ns4:p> <ns4:bold>Conclusions: </ns4:bold>As of 2020, SDI of ART was widespread, if not nearly universal, in Malawi and Zambia but considerably less common in South Africa. Limitations of the study include pre-COVID-19 data that do not reflect pandemic adaptations and potentially missing data for Zambia. South Africa may be able to increase overall ART coverage by reducing numbers of patients who do not initiate ≤6 months.</ns4:p><ns4:p> <ns4:bold>Registration:</ns4:bold> Clinicaltrials.gov (<ns4:ext-link xmlns:ns5=\"http://www.w3.org/1999/xlink\" ext-link-type=\"uri\" ns5:href=\"https://clinicaltrials.gov/show/NCT04468399\">NCT04468399</ns4:ext-link>; <ns4:ext-link xmlns:ns5=\"http://www.w3.org/1999/xlink\" ext-link-type=\"uri\" ns5:href=\"https://clinicaltrials.gov/show/NCT04170374\">NCT04170374</ns4:ext-link>; <ns4:ext-link xmlns:ns5=\"http://www.w3.org/1999/xlink\" ext-link-type=\"uri\" ns5:href=\"https://clinicaltrials.gov/show/NCT04470011\">NCT04470011</ns4:ext-link>).</ns4:p>","PeriodicalId":12593,"journal":{"name":"Gates Open Research","volume":"62 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Uptake of same-day initiation of HIV treatment among adult men and women in Malawi, South Africa, and Zambia: the SPRINT retrospective cohort study\",\"authors\":\"Amy Huber, Kamban Hirasen, Alana T. Brennan, Bevis Phiri, Timothy Tcherini, Lloyd Mulenga, Prudence Haimbe, Hilda Shakwelele, Rose Nyirenda, Bilaal Wilson Matola, Andrews Gunda, Sydney Rosen\",\"doi\":\"10.12688/gatesopenres.14424.1\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<ns4:p><ns4:bold>Background: </ns4:bold>Since 2017 global guidelines have recommended “same-day initiation” (SDI) of antiretroviral treatment (ART) for patients considered ready for treatment on the day of HIV diagnosis. Many countries have incorporated a SDI option into national guidelines, but SDI uptake is not well documented. We estimated average time to ART initiation at 12 public healthcare facilities in Malawi, five in South Africa, and 12 in Zambia.</ns4:p><ns4:p> <ns4:bold>Methods: </ns4:bold>We sequentially enrolled patients eligible to start ART between January 2018 and June 2019 and reviewed their medical records from the point of HIV diagnosis or first HIV-related interaction with the clinic to the earlier date of treatment initiation or 6 months. We estimated the proportion of patients initiating ART on the same day or within 7, 14, 30, or 180 days of baseline.</ns4:p><ns4:p> <ns4:bold>Results: </ns4:bold>We enrolled 826 patients in Malawi, 534 in South Africa, and 1,984 in Zambia. Overall, 88% of patients in Malawi, 57% in South Africa, and 91% in Zambia were offered and accepted SDI. In Malawi, most who did not receive SDI had not initiated ART ≤6 months. In South Africa, an additional 13% initiated ≤1 week, but 21% had no record of initiation ≤6 months. Among those who did initiate within 6 months in Zambia, most started ≤1 week. There were no major differences by sex. WHO Stage III/IV and tuberculosis symptoms were associated with delays in ART initiation.</ns4:p><ns4:p> <ns4:bold>Conclusions: </ns4:bold>As of 2020, SDI of ART was widespread, if not nearly universal, in Malawi and Zambia but considerably less common in South Africa. Limitations of the study include pre-COVID-19 data that do not reflect pandemic adaptations and potentially missing data for Zambia. South Africa may be able to increase overall ART coverage by reducing numbers of patients who do not initiate ≤6 months.</ns4:p><ns4:p> <ns4:bold>Registration:</ns4:bold> Clinicaltrials.gov (<ns4:ext-link xmlns:ns5=\\\"http://www.w3.org/1999/xlink\\\" ext-link-type=\\\"uri\\\" ns5:href=\\\"https://clinicaltrials.gov/show/NCT04468399\\\">NCT04468399</ns4:ext-link>; <ns4:ext-link xmlns:ns5=\\\"http://www.w3.org/1999/xlink\\\" ext-link-type=\\\"uri\\\" ns5:href=\\\"https://clinicaltrials.gov/show/NCT04170374\\\">NCT04170374</ns4:ext-link>; <ns4:ext-link xmlns:ns5=\\\"http://www.w3.org/1999/xlink\\\" ext-link-type=\\\"uri\\\" ns5:href=\\\"https://clinicaltrials.gov/show/NCT04470011\\\">NCT04470011</ns4:ext-link>).</ns4:p>\",\"PeriodicalId\":12593,\"journal\":{\"name\":\"Gates Open Research\",\"volume\":\"62 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-02-14\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Gates Open Research\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.12688/gatesopenres.14424.1\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Gates Open Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.12688/gatesopenres.14424.1","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1

摘要

背景:自2017年以来,全球指南建议对在艾滋病毒诊断当天被认为准备接受治疗的患者“当日开始”抗逆转录病毒治疗(ART)。许多国家已将SDI选项纳入国家指南,但SDI的使用情况没有很好的记录。我们估计了马拉维12个、南非5个和赞比亚12个公共医疗机构开始抗逆转录病毒治疗的平均时间。方法:我们在2018年1月至2019年6月期间依次招募符合条件的患者开始抗逆转录病毒治疗,并回顾了他们的医疗记录,从HIV诊断或首次与临床HIV相关的相互作用到开始治疗的较早日期或6个月。我们估计了在基线的同一天或在7天、14天、30天或180天内开始抗逆转录病毒治疗的患者比例。结果:我们在马拉维招募了826名患者,在南非招募了534名患者,在赞比亚招募了1984名患者。总体而言,马拉维88%的患者、南非57%的患者和赞比亚91%的患者接受了SDI治疗。在马拉维,大多数未接受SDI的患者≤6个月未开始抗逆转录病毒治疗。在南非,另外13%的人开始≤1周,但21%的人没有开始≤6个月的记录。在赞比亚6个月内开始治疗的患者中,大多数开始≤1周。性别差异不大。世卫组织III/IV期和结核病症状与延迟开始抗逆转录病毒治疗有关。结论:截至2020年,抗逆转录病毒药物的SDI在马拉维和赞比亚很普遍,如果不是几乎普遍的话,但在南非却不那么普遍。该研究的局限性包括covid -19前的数据不能反映大流行的适应情况,以及赞比亚可能缺少的数据。南非可以通过减少≤6个月未开始接受抗逆转录病毒治疗的患者人数来增加总的抗逆转录病毒治疗覆盖率。注册:Clinicaltrials.gov (NCT04468399;NCT04170374;NCT04470011)。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Uptake of same-day initiation of HIV treatment among adult men and women in Malawi, South Africa, and Zambia: the SPRINT retrospective cohort study
Background: Since 2017 global guidelines have recommended “same-day initiation” (SDI) of antiretroviral treatment (ART) for patients considered ready for treatment on the day of HIV diagnosis. Many countries have incorporated a SDI option into national guidelines, but SDI uptake is not well documented. We estimated average time to ART initiation at 12 public healthcare facilities in Malawi, five in South Africa, and 12 in Zambia. Methods: We sequentially enrolled patients eligible to start ART between January 2018 and June 2019 and reviewed their medical records from the point of HIV diagnosis or first HIV-related interaction with the clinic to the earlier date of treatment initiation or 6 months. We estimated the proportion of patients initiating ART on the same day or within 7, 14, 30, or 180 days of baseline. Results: We enrolled 826 patients in Malawi, 534 in South Africa, and 1,984 in Zambia. Overall, 88% of patients in Malawi, 57% in South Africa, and 91% in Zambia were offered and accepted SDI. In Malawi, most who did not receive SDI had not initiated ART ≤6 months. In South Africa, an additional 13% initiated ≤1 week, but 21% had no record of initiation ≤6 months. Among those who did initiate within 6 months in Zambia, most started ≤1 week. There were no major differences by sex. WHO Stage III/IV and tuberculosis symptoms were associated with delays in ART initiation. Conclusions: As of 2020, SDI of ART was widespread, if not nearly universal, in Malawi and Zambia but considerably less common in South Africa. Limitations of the study include pre-COVID-19 data that do not reflect pandemic adaptations and potentially missing data for Zambia. South Africa may be able to increase overall ART coverage by reducing numbers of patients who do not initiate ≤6 months. Registration: Clinicaltrials.gov (NCT04468399; NCT04170374; NCT04470011).
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Gates Open Research
Gates Open Research Immunology and Microbiology-Immunology and Microbiology (miscellaneous)
CiteScore
3.60
自引率
0.00%
发文量
90
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信